388 related articles for article (PubMed ID: 19550373)
21. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
[TBL] [Abstract][Full Text] [Related]
22. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases.
Zynger DL; Gupta A; Luan C; Chou PM; Yang GY; Yang XJ
Hum Pathol; 2008 Feb; 39(2):224-30. PubMed ID: 17949790
[TBL] [Abstract][Full Text] [Related]
23. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
24. Glypican-3 is expressed in chromophobe renal cell carcinomas.
OkoĊ K
Pol J Pathol; 2008; 59(1):15-20. PubMed ID: 18655366
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
[TBL] [Abstract][Full Text] [Related]
26. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
Capurro MI; Xiang YY; Lobe C; Filmus J
Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626
[TBL] [Abstract][Full Text] [Related]
27. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma.
Abdul-Al HM; Wang G; Makhlouf HR; Goodman ZD
Int J Surg Pathol; 2010 Oct; 18(5):313-8. PubMed ID: 20444731
[TBL] [Abstract][Full Text] [Related]
28. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
29. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy.
Wang FH; Yip YC; Zhang M; Vong HT; Chan KI; Wai KC; Wen JM
J Clin Pathol; 2010 Jul; 63(7):599-603. PubMed ID: 20501450
[TBL] [Abstract][Full Text] [Related]
31. Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.
Umezu T; Shibata K; Shimaoka M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Senga T; Kikkawa F
Cancer Sci; 2010 Jan; 101(1):143-8. PubMed ID: 19860840
[TBL] [Abstract][Full Text] [Related]
32. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
Filmus J; Capurro M
FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
[TBL] [Abstract][Full Text] [Related]
33. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
34. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2.
Morford LA; Davis C; Jin L; Dobierzewska A; Peterson ML; Spear BT
Hepatology; 2007 Nov; 46(5):1541-7. PubMed ID: 17668883
[TBL] [Abstract][Full Text] [Related]
35. Identification of glypican-3 as a novel tumor marker for melanoma.
Nakatsura T; Kageshita T; Ito S; Wakamatsu K; Monji M; Ikuta Y; Senju S; Ono T; Nishimura Y
Clin Cancer Res; 2004 Oct; 10(19):6612-21. PubMed ID: 15475451
[TBL] [Abstract][Full Text] [Related]
36. Glypican 3 expression in pediatric malignant solid tumors.
Kinoshita Y; Tanaka S; Souzaki R; Miyoshi K; Kohashi K; Oda Y; Nakatsura T; Taguchi T
Eur J Pediatr Surg; 2015 Feb; 25(1):138-44. PubMed ID: 25344940
[TBL] [Abstract][Full Text] [Related]
37. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
[TBL] [Abstract][Full Text] [Related]
40. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]